CSPC Pharmaceutical's (HKG:1093) SYS6043 was granted breakthrough therapy designation from China's National Medical Products Administration.
The proposed indication is for the treatment of platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer as a monotherapy, according to a Thursday filing.